[go: up one dir, main page]

NO20082559L - Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer - Google Patents

Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer

Info

Publication number
NO20082559L
NO20082559L NO20082559A NO20082559A NO20082559L NO 20082559 L NO20082559 L NO 20082559L NO 20082559 A NO20082559 A NO 20082559A NO 20082559 A NO20082559 A NO 20082559A NO 20082559 L NO20082559 L NO 20082559L
Authority
NO
Norway
Prior art keywords
ptk7
antibodies
methods
monoclonal antibodies
human monoclonal
Prior art date
Application number
NO20082559A
Other languages
English (en)
Inventor
Chin Pan
Jonathan Alexander Terrett
Li-Sheng Lu
Original Assignee
Medarex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38123515&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20082559(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medarex Llc filed Critical Medarex Llc
Publication of NO20082559L publication Critical patent/NO20082559L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Foreliggende oppfinnelse tilveiebringer isolerte monoklonale antistoffer, spesielt humane monoklonale antistoffer, som binder spesifikt til PTK7 med høy affinitet. Nukleinsyremolekyler som koder for antistoffene ifølge oppfinnelsen, ekspresjonsvektorer, vertsceller og fremgangsmåter for ekspresjon av antistoffene ifølge oppfinnelsen er også fremskaffet. Immunkonjugater, bispesifikke molekyler og farmasøytiske sammensetninger omfattende antistoffene ifølge oppfinnelsen er også fremskaffet. Foreliggende oppfinnelse tilveiebringer også fremgangsmåter for deteksjon av PTK7, så vel som fremgangsmåter for behandling av ulike sykdommer, omfattende kreft og infeksjonssykdommer, ved anvendelse av anti-PTK7-antistoffer.
NO20082559A 2005-12-08 2008-06-02 Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer NO20082559L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74837305P 2005-12-08 2005-12-08
PCT/US2006/046837 WO2007067730A2 (en) 2005-12-08 2006-12-08 Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use

Publications (1)

Publication Number Publication Date
NO20082559L true NO20082559L (no) 2008-07-07

Family

ID=38123515

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082559A NO20082559L (no) 2005-12-08 2008-06-02 Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer

Country Status (22)

Country Link
US (3) US8222375B2 (no)
EP (1) EP1957539B1 (no)
JP (1) JP5401639B2 (no)
KR (1) KR101373464B1 (no)
CN (1) CN101360761B (no)
AU (1) AU2006321841C1 (no)
BR (1) BRPI0619582A2 (no)
CA (1) CA2632552C (no)
DK (1) DK1957539T3 (no)
EA (1) EA017812B1 (no)
ES (1) ES2406063T3 (no)
HK (1) HK1121174A1 (no)
IL (1) IL191788A (no)
ME (1) ME02002B (no)
NO (1) NO20082559L (no)
NZ (2) NZ594466A (no)
PL (1) PL1957539T3 (no)
PT (1) PT1957539E (no)
RS (1) RS52804B (no)
SG (1) SG177194A1 (no)
SI (1) SI1957539T1 (no)
WO (1) WO2007067730A2 (no)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2630483C (en) * 2005-12-08 2015-05-19 Medarex, Inc. Human monoclonal antibodies to o8e
ME02002B (me) 2005-12-08 2013-10-31 Squibb & Sons Llc Humana monoklonska antitela prema proteinskoj tirozin kinazi 7 (ptk 7) i njihova upotreba
WO2009026274A1 (en) 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
US7960125B2 (en) * 2007-09-25 2011-06-14 The Board Of Trustees Of The Leland Stanford Junior University Identification of thymically derived CD4 T cells by protein tyrosine kinase 7 expression
ES2445755T3 (es) * 2007-11-07 2014-03-05 Celldex Therapeutics, Inc. Anticuerpos que se unen a células dendríticas y epiteliales humanas 205 (DEC-205)
JP2011505146A (ja) * 2007-11-30 2011-02-24 ブリストル−マイヤーズ スクイブ カンパニー タンパク質チロシンキナーゼ７（ｐｔｋ７）を対象とするモノクローナル抗体−パートナー分子複合体
WO2009116764A2 (ko) * 2008-03-17 2009-09-24 연세대학교 산학협력단 Ptk7 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제
KR101123130B1 (ko) * 2008-03-17 2012-03-30 연세대학교 산학협력단 Ｐｔｋ７ 단백질의 기능 저해를 통한 세포의 이동, 침윤 또는 혈관신생 억제제
RU2562865C2 (ru) 2009-07-10 2015-09-10 Иннэйт Фарма Tlr3 связывающие агенты
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
EP2380909A1 (en) * 2010-04-26 2011-10-26 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PTK-7 protein involved in breast cancer
US9290499B2 (en) 2010-05-19 2016-03-22 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
SA112330278B1 (ar) * 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
US8852599B2 (en) 2011-05-26 2014-10-07 Bristol-Myers Squibb Company Immunoconjugates, compositions for making them, and methods of making and use
CA2850617A1 (en) 2011-10-03 2013-04-11 The University Of North Carolina At Chapel Hill Pyrrolopyrimidine compounds for the treatment of cancer
SMT201700137T1 (it) 2012-02-13 2017-05-08 Bristol Myers Squibb Co Composti di endiini, loro coniugati, e loro usi e metodi
CN104302627A (zh) 2012-05-22 2015-01-21 北卡罗来纳大学教堂山分校 用于治疗癌症的嘧啶化合物
ES2695151T3 (es) 2012-05-31 2019-01-02 Innate Pharma Agentes de ligación a TLR3
EP2909211A4 (en) 2012-10-17 2016-06-22 Univ North Carolina PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
WO2014085225A1 (en) 2012-11-27 2014-06-05 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
JP6302490B2 (ja) 2013-02-14 2018-03-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ツブリシン化合物、その製造および使用方法
WO2015023879A1 (en) 2013-08-14 2015-02-19 William Marsh Rice University Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents
WO2015157115A1 (en) 2014-04-11 2015-10-15 The University Of North Carolina At Chapel Hill Mertk-specific pyrimidine compounds
HUE053287T2 (hu) 2014-04-30 2021-06-28 Pfizer PTK-7 elleni ellenanyag-drog konjugátumok
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
CN107250157B (zh) 2014-11-21 2021-06-29 百时美施贵宝公司 包含修饰的重链恒定区的抗体
US9526801B2 (en) 2015-01-14 2016-12-27 Bristol-Myers Squibb Company Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
JP6797137B2 (ja) 2015-05-29 2020-12-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｏｘ４０に対する抗体およびその使用
WO2017112624A1 (en) 2015-12-21 2017-06-29 Bristol-Myers Squibb Company Variant antibodies for site-specific conjugation
AU2017209083A1 (en) 2016-01-22 2018-07-12 Adimab, Llc Anti-coagulation factor XI antibodies
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
JP2019518013A (ja) 2016-05-10 2019-06-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 安定性が向上したツブリシン類似体の抗体薬物結合体
BR112018075858A2 (pt) 2016-06-14 2019-04-02 Merck Sharp & Dohme Corp. anticorpos anti-fator xi de coagulação
WO2018035391A1 (en) 2016-08-19 2018-02-22 Bristol-Myers Squibb Company Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
WO2018075842A1 (en) 2016-10-20 2018-04-26 Bristol-Myers Squibb Company Condensed benzodiazepine derivatives and conjugates made therefrom
MX2019013132A (es) 2017-05-25 2020-01-27 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas.
US10494370B2 (en) 2017-08-16 2019-12-03 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
US10508115B2 (en) 2017-08-16 2019-12-17 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
US10472361B2 (en) 2017-08-16 2019-11-12 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor
US10487084B2 (en) 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
US10457681B2 (en) 2017-08-16 2019-10-29 Bristol_Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a tricyclic moiety, conjugates thereof, and methods and uses therefor
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
IL278938B2 (en) 2018-05-29 2024-09-01 Bristol Myers Squibb Co Modified self-immolating moieties for use in prodrugs and conjugates and methods of using and making
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
BR112021008083A2 (pt) * 2018-11-07 2021-08-10 Crispr Therapeutics Ag terapia contra o câncer com célula imunológica anti-ptk7
US20220106400A1 (en) 2018-11-28 2022-04-07 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
SMT202300159T1 (it) 2018-11-30 2023-07-20 Bristol Myers Squibb Co Anticorpo comprendente un’estensione carbossiterminale della catena leggera contenente glutammina, suoi coniugati e metodi ed usi
US20220031860A1 (en) 2018-12-12 2022-02-03 Bristol-Myers Squibb Company Antibodies modified for transglutaminase conjugation, conjugates thereof, and methods and uses
KR102236127B1 (ko) * 2019-08-08 2021-04-07 주식회사 하울바이오 티로시나아제를 억제하는 항-티로시나아제 항체 및 이의 용도
WO2021055306A1 (en) 2019-09-16 2021-03-25 Bristol-Myers Squibb Company Dual capture method for analysis of antibody-drug conjugates
TW202208412A (zh) * 2020-05-06 2022-03-01 瑞士商Ｃｒｉｓｐｒ治療公司 對酪胺酸蛋白激酶樣７（ｐｔｋ７）特異的經掩蔽的嵌合抗原受體和表現其的免疫細胞
WO2022015113A1 (ko) * 2020-07-16 2022-01-20 연세대학교 산학협력단 Ptk7에 특이적으로 결합하는 항체 및 이의 용도
CN115894696A (zh) * 2021-08-18 2023-04-04 和迈生物科技有限公司 抗ptk7单域抗体及其应用
CN114213541B (zh) * 2021-12-20 2022-12-30 南京诺唯赞生物科技股份有限公司 一种全能核酸酶的单克隆抗体及其制备方法
KR20250024742A (ko) 2022-03-23 2025-02-19 시나픽스 비.브이. Ptk7을 발현하는 종양을 표적화하기 위한 항체-컨쥬게이트
EP4526345A1 (en) 2022-05-19 2025-03-26 Mythic Therapeutics, Inc. Ptk7-binding proteins with ph-dependent binding and uses thereof
GB202209196D0 (en) * 2022-06-22 2022-08-10 Almac Discovery Ltd Bi-specific antigen binding molecules
TW202417516A (zh) * 2022-08-19 2024-05-01 大陸商四川科倫博泰生物醫藥股份有限公司 Ptk7結合蛋白及其用途
WO2024054030A1 (ko) * 2022-09-06 2024-03-14 연세대학교 산학협력단 항-ptk7 항체 및 이의 용도
TW202421657A (zh) * 2022-10-14 2024-06-01 日商Ｊｓｒ股份有限公司 抗體或其片段、抗癌劑及抗癌用藥物組成物
WO2024193679A1 (en) * 2023-03-23 2024-09-26 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Antibodies and uses thereof
CN118852442A (zh) * 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708930A (en) * 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
AU6238696A (en) * 1995-05-25 1996-12-11 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders
JPH11513391A (ja) 1995-10-03 1999-11-16 ザ スクリップス リサーチ インスティテュート Ｃｃ−１０６５ 及びズオカーマイシンのｃｂｉ 類縁体
AU6887698A (en) 1997-04-08 1998-10-30 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
EP0983248B1 (en) 1997-05-22 2004-07-14 The Scripps Research Institute Analogs of duocarmycin and cc-1065
CA2380813A1 (en) 1999-07-29 2001-02-08 Medarex, Inc. Human monoclonal antibodies to her2/neu
CA2440703A1 (en) 2001-01-24 2002-08-01 Protein Design Labs, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
CA2444691A1 (en) 2001-04-18 2002-10-31 Protein Design Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
CN101671335A (zh) 2001-05-31 2010-03-17 梅达莱克斯公司 细胞毒素、其有用的前体药物、连接基团和稳定剂
GB0114033D0 (en) 2001-06-09 2001-08-01 Innovata Biomed Ltd Process
ES2364452T3 (es) 2001-06-11 2011-09-02 Medarex, Inc. Método para diseñar compuestos profármacos activados por cd10.
KR20090125840A (ko) 2001-06-13 2009-12-07 젠맵 에이/에스 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간 모노클로날 항체
US20040076955A1 (en) 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
EP1423110A4 (en) 2001-09-07 2005-04-27 Scripps Research Inst CBI ANALOGUE OF CC-1065 AND DUOCARMYCINES
JP2003088388A (ja) * 2001-09-14 2003-03-25 Herikkusu Kenkyusho:Kk 新規な全長ｃＤＮＡ
WO2003025138A2 (en) 2001-09-17 2003-03-27 Protein Design Labs, Inc. Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
AU2002362646A1 (en) * 2001-10-09 2003-04-22 The Johns Hopkins University A phosphatase associated with metastasis
WO2003042661A2 (en) 2001-11-13 2003-05-22 Protein Design Labs, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2003055527A2 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
WO2003059951A2 (fr) * 2002-01-18 2003-07-24 Pierre Fabre Medicament Anticorps anti-igf-ir et leurs applications
WO2004006838A2 (en) 2002-07-15 2004-01-22 Sugen, Inc. Novel kinases
GB0219776D0 (en) * 2002-08-24 2002-10-02 Oxford Glycosciences Uk Ltd A protein involved in carcinoma
ATE488588T1 (de) * 2003-03-10 2010-12-15 Japan Science & Tech Agency Verfahren zur kennzeichnung mesenchymaler stammzellen unter verwendung verschiedener marker
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005063987A1 (en) 2003-12-19 2005-07-14 Aveo Pharmaceuticals, Inc. Gp153: methods and compositions for treating cancer
BRPI0510367A (pt) 2004-04-29 2007-11-06 Genzyme Corp métodos e composições para o tratamento de doenças policìsticas
JP4806680B2 (ja) 2004-05-19 2011-11-02 メダレックス インコーポレイテッド 自己犠牲リンカー及び薬剤複合体
US7691962B2 (en) 2004-05-19 2010-04-06 Medarex, Inc. Chemical linkers and conjugates thereof
EP1781318A4 (en) * 2004-06-23 2009-12-23 Genzyme Corp METHODS AND COMPOSITIONS FOR THE TREATMENT OF POLYKYSTIC DISEASES
WO2006110593A2 (en) 2005-04-07 2006-10-19 Macrogenics, Inc. Biological targets for the diagnosis, treatment and prevention of cancer
AU2006294554B2 (en) 2005-09-26 2013-03-21 E. R. Squibb & Sons, L.L.C. Antibody-drug conjugates and methods of use
ME02002B (me) 2005-12-08 2013-10-31 Squibb & Sons Llc Humana monoklonska antitela prema proteinskoj tirozin kinazi 7 (ptk 7) i njihova upotreba
JP2011505146A (ja) 2007-11-30 2011-02-24 ブリストル−マイヤーズ スクイブ カンパニー タンパク質チロシンキナーゼ７（ｐｔｋ７）を対象とするモノクローナル抗体−パートナー分子複合体
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos

Also Published As

Publication number Publication date
EA200801509A1 (ru) 2008-12-30
BRPI0619582A2 (pt) 2012-12-11
EA017812B1 (ru) 2013-03-29
NZ594466A (en) 2012-08-31
US20120219557A1 (en) 2012-08-30
CN101360761B (zh) 2012-09-12
DK1957539T3 (da) 2013-05-06
ES2406063T3 (es) 2013-06-05
IL191788A (en) 2014-06-30
IL191788A0 (en) 2009-02-11
US9505845B2 (en) 2016-11-29
AU2006321841B2 (en) 2012-08-30
US20100034826A1 (en) 2010-02-11
HK1121174A1 (en) 2009-04-17
JP2009518039A (ja) 2009-05-07
SG177194A1 (en) 2012-01-30
US20120207764A1 (en) 2012-08-16
PL1957539T3 (pl) 2013-08-30
AU2006321841A1 (en) 2007-06-14
ME02002B (me) 2013-10-31
CA2632552C (en) 2015-02-03
PT1957539E (pt) 2013-06-25
KR20080082660A (ko) 2008-09-11
CA2632552A1 (en) 2007-06-14
KR101373464B1 (ko) 2014-03-14
US9102738B2 (en) 2015-08-11
AU2006321841C1 (en) 2013-01-24
EP1957539B1 (en) 2013-04-17
JP5401639B2 (ja) 2014-01-29
NZ569236A (en) 2012-06-29
RS52804B (en) 2013-10-31
SI1957539T1 (sl) 2013-05-31
WO2007067730A2 (en) 2007-06-14
EP1957539A2 (en) 2008-08-20
WO2007067730A3 (en) 2007-11-01
CN101360761A (zh) 2009-02-04
US8222375B2 (en) 2012-07-17

Similar Documents

Publication Publication Date Title
NO20082559L (no) Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer
NO20092285L (no) Humane, monoklonale antistoffer til BTLA og fremgangsmater for anvendelse
NO20080590L (no) Humane, monoklonale antistoffer mot programmert dodsligand (PD-L1)
NO20081987L (no) Humane, monoklonale antistoffer mot CD70
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
NO20083053L (no) Humane monoklonale antistoffer mot O8E
NO20064866L (no) IRTA-5 antistoffer og deres anvendelse
NO20091283L (no) Humane antistoffer som binder CXCR4 og anvendelser derav
NO20073797L (no) Humane monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA)
CY1121648T1 (el) ΑΝΘΡΩΠΙΝΑ ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ΠΡΟΣ ΠΡΟΓΡΑΜΜΑΤΙΣΜΕΝΟ ΘΑΝΑΤΟ l(PD-l) ΚΑΙ ΜΕΘΟΔΟΙ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΚΑΡΚΙΝΟΥ ΧΡΗΣΙΜΟΠΟΙΩΝΤΑΣ ANTI-PD-1 ΑΝΤΙΣΩΜΑΤΑ ΜΟΝΑ Ή ΣΕ ΣΥΝΔΥΑΣΜΟ ΜΕ ΑΛΛΕΣ ΑΝΟΣΟΘΕΡΑΠΕΥΤΙΚΕΣ
NO20080362L (no) CD19-antistoffer og deres anvendelser
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
DE602005027258D1 (de) Humane monoklonale antikörper gegen hendra- und nipah-viren
EA200901436A1 (ru) Антигенсвязывающие белки, связывающие par-2
MEP53308A (en) Novel peptides that bind to the erythropoietin receptor
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
EA201101516A1 (ru) Антитела, специфические для кадгерина-17
NO20092360L (no) Nye antiproliferasjonsantistoffer
DE602005027399D1 (de) Für humane matriptase spezifische bindungsproteine
WO2008109533A3 (en) Human antibodies that bind multiple irta family proteins, and uses thereof
WO2006116192A3 (en) Irta-1 antibodies and their uses
EA200700990A1 (ru) Новые пептиды, которые связывают рецептор эритропоэтина
CY1116843T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα προς συνδετη 1 προγραμματισμενου θανατου (pd-l1)
CY1114151T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα ως προς την κιναση τυροσινης πρωτεϊνης 7 (ρτκ7) και η χρηση αυτων
CY1113958T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα σε φουκοζυλ-gμ1 και μεθοδοι για τη χρηση αντι-φουκοζυλ-gμ1

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MEDAREX LLC, US

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: E.R. SQUIBB & SONS, US

FC2A Withdrawal, rejection or dismissal of laid open patent application